Literature DB >> 22644068

High acceptability of a vaginal ring intended as a microbicide delivery method for HIV prevention in African women.

A van der Straten1, E T Montgomery, H Cheng, L Wegner, G Masenga, C von Mollendorf, L Bekker, S Ganesh, K Young, J Romano, A Nel, C Woodsong.   

Abstract

Vaginal rings (VRs) are new methods for continuous delivery of microbicides. This is the first study to quantitatively and qualitatively explore the acceptability of rings in Africa: 157 HIV-negative, sexually active women aged 18-35 used a placebo silicone elastomer ring for 12 weeks. They completed product acceptability questionnaires every 4 weeks. We conducted 6 exit focus group discussions with a subset of 48 women and 19 in-depth interviews with male partners. Retention in the study was high (97 %). Initial insertion at the clinic was successful on first attempt for 81 % of participants. Most women were comfortable using the ring, and very few (≤2 %) could feel it during daily activities or had ring-related physical or emotional problems. In the qualitative interviews many participants reported that they initially had concerns about using the ring. However, only a minority of women actually reported concerns with the ring during the study. The most frequent concern was that the ring would get lost inside the body (20 %), and this was significantly correlated with study site, frequently thinking about the ring and reporting that the ring was not very easy to remove. Qualitative data suggest that informants grew to like the ring because it felt securely placed, was unnoticeable during daily activities, and felt "normal" during sex. The ring appeared to be highly acceptable for women and men. Initial concerns with this novel method suggest a need for enhanced product counseling when VRs are introduced.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22644068     DOI: 10.1007/s10461-012-0215-0

Source DB:  PubMed          Journal:  AIDS Behav        ISSN: 1090-7165


  56 in total

Review 1.  Drug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug delivery.

Authors:  Minlu Hu; Sravan Kumar Patel; Tian Zhou; Lisa C Rohan
Journal:  J Control Release       Date:  2015-08-13       Impact factor: 9.776

2.  Reasons for nonadherence to the dapivirine vaginal ring: narrative explanations of objective drug-level results.

Authors:  Elizabeth T Montgomery; Jonathan Stadler; Sarita Naidoo; Ariana W K Katz; Nicole Laborde; Morgan Garcia; Krishnaveni Reddy; Leila E Mansoor; Juliane Etima; Chifundo Zimba; Miria Chitukuta; Lydia Soto-Torres
Journal:  AIDS       Date:  2018-07-17       Impact factor: 4.177

3.  Acceptability and use of a dapivirine vaginal ring in a phase III trial.

Authors:  Elizabeth T Montgomery; Ariane van der Straten; Miria Chitukuta; Krishnaveni Reddy; Kubashni Woeber; Millicent Atujuna; Linda-Gail Bekker; Juliane Etima; Teopista Nakyanzi; Ashley J Mayo; Ariana Katz; Nicole Laborde; Cynthia I Grossman; Lydia Soto-Torres; Thesla Palanee-Phillips; Jared M Baeten
Journal:  AIDS       Date:  2017-05-15       Impact factor: 4.177

4.  Relationship Type and Use of the Vaginal Ring for HIV-1 Prevention in the MTN 020/ASPIRE Trial.

Authors:  E Pleasants; T Tauya; K Reddy; B G Mirembe; K Woeber; T Palanee-Phillips; C Zimba; M Atujuna; E T Montgomery
Journal:  AIDS Behav       Date:  2020-03

5.  A Qualitative Systematic Review of Women's Experiences Using Contraceptive Vaginal Rings: Implications for New Technologies.

Authors:  Sara E Vargas; Miriam M Midoun; Melissa Guillen; Melissa L Getz; Kristen Underhill; Caroline Kuo; Kate M Guthrie
Journal:  Perspect Sex Reprod Health       Date:  2019-05-20

6.  Frequent Cross-Resistance to Dapivirine in HIV-1 Subtype C-Infected Individuals after First-Line Antiretroviral Therapy Failure in South Africa.

Authors:  Kerri J Penrose; Carole L Wallis; Chanson J Brumme; Kristen A Hamanishi; Kelley C Gordon; Raquel V Viana; P Richard Harrigan; John W Mellors; Urvi M Parikh
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

Review 7.  Acceptability in microbicide and PrEP trials: current status and a reconceptualization.

Authors:  Barbara S Mensch; Ariane van der Straten; Lauren L Katzen
Journal:  Curr Opin HIV AIDS       Date:  2012-11       Impact factor: 4.283

8.  Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges.

Authors:  James M Smith; Rachna Rastogi; Ryan S Teller; Priya Srinivasan; Pedro M M Mesquita; Umadevi Nagaraja; Janet M McNicholl; R Michael Hendry; Chuong T Dinh; Amy Martin; Betsy C Herold; Patrick F Kiser
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-16       Impact factor: 11.205

9.  In search of the optimal delivery method for anti-HIV microbicides: are intravaginal rings the way forward?

Authors:  Nina Derby; Thomas Zydowsky; Melissa Robbiani
Journal:  Expert Rev Anti Infect Ther       Date:  2013-01       Impact factor: 5.091

10.  Characteristics of women screened for a contraceptive intravaginal ring study in Kisumu, Kenya, 2014.

Authors:  Eleanor McLellan-Lemal; Deborah A Gust; Roman Gvetadze; Melissa Furtado; Fredrick O Otieno; Mitesh Desai; Clement Zeh; Taraz Samandari; Beatrice Nyagol; Esther M Makanga
Journal:  Res J Womens Health       Date:  2016-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.